Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
The New York Proton Center
Beijing Biotech
Parabilis Medicines, Inc.
Orano Med LLC
Filamon LTD
AstraZeneca
UMC Utrecht
Essen Biotech
Essen Biotech
Sapience Therapeutics
University of Nebraska
Adela, Inc
Dysplasia Diagnostics Limited
Mayo Clinic
Mayo Clinic
Dana-Farber Cancer Institute
Massive Bio, Inc.
Incyte Corporation
AVM Biotechnology Inc
Maastricht Radiation Oncology
Massachusetts General Hospital
Dana-Farber Cancer Institute
Washington University School of Medicine
Fudan University
Jonsson Comprehensive Cancer Center
University of California, San Francisco
Columbia University
Tempus AI